Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

October 01, 2026

Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗

Performance

52-Week Range 45.7% below 52-week high

3.965

3.4652W Low 7.3052W High

1 Week 7.0% below 1-week high

3.501W Low 4.261W High

Taysha Gene Therapies, Inc. - Common Stock (TSHA) traded between $3.46 and $7.30 over the past 52 weeks and last traded at $3.96, 45.7% below its 52-week high. Over the past week it ranged between $3.50 and $4.26.

Past 12 Months

+6.3%

-21.3%

-29.9%

-41.0%

-24.5%

-23.0%

1W +$0.23

1M -$1.08

3M -$1.70

6M -$2.75

YTD -$1.29

1Y -$1.19

TSHA was -23.0% over the past year, -41.0% over six months, -24.5% year to date, +6.3% in the last week.

12 Months vs Market

TSHA

-23.0%

DIA

+12.3%

SPY

+13.6%

QQQ

+15.2%

IWM

+11.9%

Over the past 12 months TSHA returned -23.0% versus DIA (Dow) +12.3%, SPY (S&P 500) +13.6%, QQQ (Nasdaq 100) +15.2% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 0.55× 3-mo avg

Today 1,945,249 3-mo avg 3.5M

5.5M

4.8M

3.5M

3.3M

YTD

3.1M

3.2M

TSHA most recently traded 1,945,249 shares against a 3-month average daily volume of 3.5M.

More News

These 3 Risky Stocks Could Be Sitting on 100% Upside ↗

September 07, 2026

Via MarketBeat

May 06, 2026

Via Chartmill

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 04, 2026

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call ↗

August 18, 2026

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Taysha Gene Therapies Q2 Earnings Call Highlights ↗

August 11, 2026

Via MarketBeat

August 11, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 07, 2026

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 04, 2026

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 03, 2026

Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗

July 12, 2026

Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting

June 25, 2026

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

June 24, 2026

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 24, 2026

Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome

June 22, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 05, 2026

Taysha (TSHA) Q1 2026 Earnings Transcript ↗

May 07, 2026

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 06, 2026

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

April 29, 2026

Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting

April 27, 2026

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 03, 2026

Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA

April 02, 2026

Via MarketMinute

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗

March 22, 2026

Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗

March 19, 2026